Stem Cell Clinic

What are Embryonic Stem Cells? – amaskincare.com

By adminAugust 19, 2017Embryonic Stem Cells

Essentially all of the Cells of aDeveloping Embryo are Stem Cells

Embryonic stem cells are derived from embryos before to the 2nd week of development long before the developing embryo has transitioned to becoming a Fetus. During these first two weeks, essentially all of the cells of the embryo are stem cells, in that they have not differentiated into cells with specialized functions. Typically embryonic stem cells are derived from embryos that are created in laboratory conditions, not harvested directly from a human mother. In other words, a human egg has been harvested from a woman and fertilized with a human sperm in vitro (in a laboratory). Thus usually takes place in an in vitro fertilization clinicand then donated for research purposes.

The technique of growing cells in the laboratory is referred to as cell culture. Human embryonic stem cells (hESCs) are grown by harvesting the cells derived from an early stage preimplantation embryo (a very young embryo that if present in a human mother would not yet be implanted in her uterus). These cells are grown in a special laboratory dish that contains a nutrient broth known as culture medium.

Once the cells have taken hold and are surviving they can be removed and placed into several additional culture dishes. The process is called sub-culturing the cells and can be repeated many times over many weeks and months. Each cycle of sub-culturing the cells is referred to as a passage, and is a way that a few original stem cells can be expanded into many generations and millions of stem cells and are referred to as an embryonic stem cell line.

During the process of generating lines of embryonic stem cells in laboratory conditions, it is important to test the cells to see if they exhibit the basic properties or characteristics of stems cells. This process is called characterization.

Though this process has not been standardized throughout the cell-biology industry, the following are some of the tests that are commonly performed:

Perhaps an even better question to ask is how do we induce stem cells to differentiate into the exact tissue or organ we need?

Let me explain. Obviously, the holy grail of regenerative medicine and stem cell therapy would be to grow a new organ lets say a liver for a patient who has a diseased liver. In such a world, any damaged or diseased organ could simply be replaced by a new young organ generated right from the patients own stem cells.

The hope is that by changing the composition of the nutrient base in which the cells are cultivated, or by adding certain transcription factors, or by using any number of chemical, biochemical and electronic elements, we might find the correct recipe for inducing a stem cell to differentiate into the cells we need or want. Though we have discovered some basic protocols for limited induction of stem cells into specific organ tissues, we are far from growing a complete and viable human organ.

To date our best hope is focusing on developing a specific cell type and not the entire organ. For example the cells that produce insulin within a pancreas, but not the entire pancreas.

More:
What are Embryonic Stem Cells? - amaskincare.com

Woman Will Use Stem Cells From Her Baby’s Umbilical Cord To … – LifeNews.com

By adminAugust 19, 2017Embryonic Stem Cells

A pregnant British mom hopes she and her unborn baby will be the answer to help prolong her ailing brothers life.

Georgina Russell, of Preston, England, said she was desperate to help her brother, Ashley, when doctors diagnosed him with a slow-growing but deadly brain tumor earlier this year, according to the Daily Mail.

Georgina said she began researching his condition, glioblastoma, online and looking for answers that could save his life. She found one: her pregnancy.

Stem cells produced in the umbilical cord between her and her unborn baby potentially could be used in a treatment to shrink Ashleys tumor, according to the report. Once Georgina gives birth, she said doctors will be able to harvest and store the stem cells until Ashley needs them.

There is no harm to the baby or the mother when doctors harvest stem cells from the umbilical cord unlike embryonic stem cells, which only can be taken by killing a human life in the embryonic stage.

Georgina told the Mail: The blood from the cord is being used in trials across the world. It can do amazing things to help the body repair itself. If we store the stem cells, they can be kept to be used throughout Ashleys treatment when he needs them.

They might be able to inject them into the spinal fluid, to shrink the tumour on the brain, or they may be able to use the tissue grown from them to repair any damage to other parts of his body, if he has to have chemotherapy or radiotherapy.

Ashley Russell, a British military veteran, husband and father, said doctors found the tumor after he began suffering from headaches, dizzy spells and mini-seizures about six months ago. Later, he said he also began having blurred vision. Doctors ran a series of tests before discovering the tumor on his brain.

He said doctors suggested surgery, but the procedure has high risks. They gave him about five years to live, according to the report.

Georgina said she was devastated for her brother and his family, and she began researching ways to help him. In her research online, she said she discovered how stem cells collected from the umbilical cord are helping to treat people with tumors and other diseases.

PRO-LIFE COLLEGE STUDENT? LifeNews is looking for interns interested in writing, social media, or video creation. Contact us today.

Her brother said the idea seemed odd at first, but he is willing to try anything.

I am quite a positive person so although the diagnosis was difficult, I am determined to do whatever I can to keep going, Ashley said. I did think about not being around to see my little girl get married and knew that if there was anything that might help, I would give it a go.

Georgina currently is 33 weeks pregnant with her unborn child, the report states.

Stem cells are so powerful and his new niece or nephew could save his life, she said.

The family set up a JustGiving page to help pay for the storage of the stem cells and Ashleys treatment.

Adult stem cells and those from umbilical cords are proving to be live-saving, while life-destroying embryonic stem cells have not been effective.

David Prentice, vice president and research director for the Charlotte Lozier Institute, explained more about the effectiveness of these life-saving stem cells in 2014:

SUPPORT PRO-LIFE NEWS! Please help LifeNews.com with a donation

Umbilical cord blood stem cells have become an extremely valuable alternative to bone marrow adult stem cell transplants, ever since cord blood stem cells were first used for patients over 25 years ago. The first umbilical cord blood stem cell transplant was performed in October 1988, for a 5-year-old child with Fanconi anemia, a serious condition where the bone marrow fails to make blood cells. That patient is currently alive and healthy, 25 years after the cord blood stem cell transplant.

Prentice said more than 30,000 cord blood stem cell transplants have been done across the world. These stem cells have helped treat people with blood and bone marrow diseases, leukemia and genetic enzyme diseases, he said.

See the original post here:
Woman Will Use Stem Cells From Her Baby's Umbilical Cord To ... - LifeNews.com

Stem cells mimic sphere where embryos grow – Futurity: Research News

By adminAugust 19, 2017Embryonic Stem Cells

Researchers report that they have coaxed pluripotent human stem cells to grow on a specially engineered surface into structures that resemble the amniotic sac.

Gumucio likens a PASE to a mismatched plastic Easter egg or a blue-and-red Pokmon ballwith two clearly divided halves of two kinds of cells

The first few weeks after sperm meets egg still hold many mysteries. Among them: what causes the process to fail, leading to many cases of infertility. Despite the importance of this critical stage, scientists havent had a good way to explore what can go wrong, or even what must go right, after the newly formed ball of cells implants in the wall of the human uterus.

But the new achievement with human stem cells may help change that. The tiny lab-grown structures could give researchers a chance to see what they couldnt before, while avoiding ethical issues associated with studying actual embryos.

The stem cells researchers used spontaneously developed some of the same structural and molecular features seen in a natural amniotic sac, which is an asymmetric, hollow ball-like structure containing cells that will give rise to a part of the placenta as well as the embryo itself.

But the structures lack other key components of the early embryo, so they cant develop into a fetus.

Its the first time a team has grown such a structure starting with stem cells, rather than coaxing a donated embryo to grow, as a few other teams have done.

As many as half of all pregnancies end in the first two weeks after fertilization, often before the woman is even aware she is pregnant. For some couples, there is a chronic inability to get past these critical early developmental steps, but we have not previously had a model that would allow us to explore the reasons why, says co-senior author Deborah Gumucio, professor of cell and developmental biology and professor of internal medicine at the University of Michigan.

We hope this work will make it possible for many scientists to dig deeper into the pathways involved in normal and abnormal development, so we can understand some of the most fascinating biology on earth.

The researchers have dubbed the new structure a post-implantation amniotic sac embryoid, or PASE. They describe how a PASE develops as a hollow spherical structure with two distinct halves that remain stable even as cells divide.

One half is made of cells that will become amniotic ectoderm, the other half consists of pluripotent epiblast cells that in nature make up the embryonic disc. The hollow center resembles the amniotic cavitywhich in normal development eventually gives rise to the fluid-filled sac that protects and cushions the fetus during development.

Gumucio likens a PASE to a mismatched plastic Easter egg or a blue-and-red Pokmon ballwith two clearly divided halves of two kinds of cells that maintain a stable form around a hollow center.

The team also reports details about the genes that became activated during the development of a PASE, and the signals that the cells in a PASE send to one another and to neighboring tissues. They show that a stable two-halved PASE structure relies on a signaling pathway called BMP-SMAD thats known to be critical to embryo development.

Gumucio says that the PASE structures even exhibit the earliest signs of initiating a primitive streak, although it did not fully develop. In a human embryo, the streak would start a process called gastrulation. Thats the division of new cells into three cell layersendoderm, mesoderm, and ectodermthat are essential to give rise to all organs and tissues in the body.

Besides working with genetic and infertility specialists to delve deeper into PASE biology as it relates to human infertility, the research team is hoping to explore additional characteristics of amnion tissue.

For example, early rupture of the amnion tissue can endanger a fetus or be the cause of a miscarriage. The team also intends to study which aspects of human amnion formation also occur in development of mouse amnion. The mouse embryo model is very attractive as an in vivo model for investigating human genetic diseases.

The research appears in the journal Nature Communications.

The teams work is overseen by a panel that monitors all work done with pluripotent stem cells at the university, and the studies are performed in accordance with laws regarding human stem cell research. The team ends experiments before the balls of cells effectively reach 14 developmental days, the cutoff used as an international limit on embryo researcheven though the work involves tissue that cannot form an embryo.

Some of the stem cell lines were derived at the University of Michigans privately funded MStem Cell Laboratory for human embryonic stem cells and the universitys Pluripotent Stem Cell Core.

The National Institutes of Health and the universitys Mechanical Engineering Startup Fund as well as the Rackham Predoctoral Fellowship funded the research. The team has worked with the universitys Office of Technology Transfer to apply for a patent on the method of generating amnion, for potential commercial use in wound healing.

Source: University of Michigan

Visit link:
Stem cells mimic sphere where embryos grow - Futurity: Research News

Vitamin C helps genes to kill off cells that would cause cancer – New Scientist

By adminAugust 19, 2017Embryonic Stem Cells

Could vitamin C help drugs fight leukaemia?

Steve Gschmeissner/SPL/Getty

By Aylin Woodward

Injections of vitamin C could be a way to help fight blood cancer. Experiments in mice suggest that the nutrient helps tell out-of-control cells to stop dividing and die.

Some blood cancers, including acute and chronic leukaemia, often involve mutations affecting a gene called TET2. This gene usually helps ensure that a type of stem cell matures properly to make white blood cells, and then eventually dies. But when TET2 mutates, these cells can start dividing uncontrollably, leading to cancer. Mutations in TET2 are involved in around 42,500 cancers in the US a year.

Luisa Cimmino and Benjamin Neel at the New York University School of Medicine and their colleagues have genetically engineered mice to have variable TET2 function. They found that a 50 per cent reduction in TET2 activity can be enough to induce cancer, but that TET2 activity needs to remain low if the disease is to continue developing. If we genetically restore TET2, it blocks unhealthy replication and kills the cells, says Cimmino.

Next, the team turned to vitamin C, because it is known to have an effect in embryonic stem cells, where it can activate TET2 and help keep cell replication in check.

The team injected mice with low TET2 activity with very high doses of vitamin C every day for 24 weeks and found that it slowed the progression of leukaemia. By the end of this period, a control group that got no injections had three times as many white blood cells a sign of pre-leukaemia.

When the team exposed human leukaemia cells in a dish to a cancer drug, they found they got better results when they added vitamin C.

Neel hopes that high doses of vitamin C will eventually be incorporated into cancer therapies. People who have acute myeloid leukemia are often of advanced age, and may die from chemotherapy. Vitamin C in combination with cancer drugs may provide an alternative approach.

But taking large amounts of vitamin C is unlikely to prevent you from getting cancer, says Neel. The mice were given 100 milligrams of vitamin C in each injection, the equivalent of about two oranges. But the average person weighs about 3000 times as much as a mouse. Because the body stops taking in the vitamin after around 500 milligrams, any therapies would need to supply vitamin C intravenously. You cant get the levels of it necessary to achieve the effects in this study by eating oranges, he says.

Journal reference: Cell, DOI: 10.1026/j.cell.2017.07.032

Read more: Choosing alternative cancer treatment doubles your risk of death

Forever Labs preserves young stem cells to prevent your older self from aging – TechCrunch

By adminAugust 17, 2017Stem Cell Treatment

Forever Labs, a startup in Y Combinators latest batch, is preserving adult stem cells with the aim to help you live longer and healthier.

Stem cells have the potential to become any type of cell needed in the body. Its very helpful to have younger stem cells from your own body on hand should you ever need some type of medical intervention, like a bone marrow transplant as the risk of rejection is greatly reduced when the cells are yours.

Mark Katakowski spent the last 15 years studying stem cells. What he found is that not only do we have less of them the older we get, but they also lose their function as we age.So, he and his co-founders Edward Cibor and Steve Clausnitzer started looking at how to bank them while they were young.

Clausnitzer banked his cells two years ago at the age of 38. So, while he is biologically now age 40, his cells remain the age in which they were harvested or as he calls it, stem cell time travel.

Steven Clausnitzer with his 38-year-old banked stem cells.

There are places offering stem cell therapy and Botox, he said.

Forever Labs is backed by a team of Ivy League-trained scientists with decades of experience between them. Jason Camm, chief medical officer for Thiel Capital, is also one of the companys medical advisors however, the startup is quick to point out it is not associated with Thiel Capital.

The process involves using a patented device to collect the cells. Forever Labs can then grow and bank your cells for $2,500, plus another $250 for storage per year (or a flat fee of $7,000 for life).

The startup is FDA-approved to bank these cells and is offering the service in seven states. What it does not have FDA approval for is the modification of those cells for rejuvenation therapy.

Katakowski refers to what the company is doing as longevity as a service, with the goal being to eventually take your banked cells and modify them to reverse the biological clock.

But that may take a few years. There are hundreds of clinical trials looking at stem cell uses right now. Forever Labs has also proposed its own clinical trial to take your stem cells and give them to your older cells.

Youll essentially young-blood effect yourself, Katakowski joked of course, in this case, youd be using your own blood made from your own stem cells, not the blood of random teens.

See more here:
Forever Labs preserves young stem cells to prevent your older self from aging - TechCrunch

UCLA scientists identify a new way to activate stem cells to make hair grow – UCLA Newsroom

By adminAugust 17, 2017Stell Cell Research

UCLA researchers have discovered a new way to activate the stem cells in the hair follicle to make hair grow. The research, led by scientists Heather Christofk and William Lowry, may lead to new drugs that could promote hair growth for people with baldness or alopecia, which is hair loss associated with such factors as hormonal imbalance, stress, aging or chemotherapy treatment.

The research was published in the journal Nature Cell Biology.

Hair follicle stem cells are long-lived cells in the hair follicle; they are present in the skin and produce hair throughout a persons lifetime. They are quiescent, meaning they are normally inactive, but they quickly activate during a new hair cycle, which is when new hair growth occurs. The quiescence of hair follicle stem cells is regulated by many factors. In certain cases they fail to activate, which is what causes hair loss.

In this study, Christofk and Lowry, of Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, found that hair follicle stem cell metabolism is different from other cells of the skin. Cellular metabolism involves the breakdown of the nutrients needed for cells to divide, make energy and respond to their environment. The process of metabolism uses enzymes that alter these nutrients to produce metabolites. As hair follicle stem cells consume the nutrient glucose a form of sugar from the bloodstream, they process the glucose to eventually produce a metabolite called pyruvate. The cells then can either send pyruvate to their mitochondria the part of the cell that creates energy or can convert pyruvate into another metabolite called lactate.

Our observations about hair follicle stem cell metabolism prompted us to examine whether genetically diminishing the entry of pyruvate into the mitochondria would force hair follicle stem cells to make more lactate, and if that would activate the cells and grow hair more quickly, said Christofk, an associate professor of biological chemistry and molecular and medical pharmacology.

The research team first blocked the production of lactate genetically in mice and showed that this prevented hair follicle stem cell activation. Conversely, in collaboration with the Rutter lab at University of Utah, they increased lactate production genetically in the mice and this accelerated hair follicle stem cell activation, increasing the hair cycle.

Before this, no one knew that increasing or decreasing the lactate would have an effect on hair follicle stem cells, said Lowry, a professor of molecular, cell and developmental biology. Once we saw how altering lactate production in the mice influenced hair growth, it led us to look for potential drugs that could be applied to the skin and have the same effect.

The team identified two drugs that, when applied to the skin of mice, influenced hair follicle stem cells in distinct ways to promote lactate production. The first drug, called RCGD423, activates a cellular signaling pathway called JAK-Stat, which transmits information from outside the cell to the nucleus of the cell. The research showed that JAK-Stat activation leads to the increased production of lactate and this in turn drives hair follicle stem cell activation and quicker hair growth. The other drug, called UK5099, blocks pyruvate from entering the mitochondria, which forces the production of lactate in the hair follicle stem cells and accelerates hair growth in mice.

Through this study, we gained a lot of interesting insight into new ways to activate stem cells, said Aimee Flores, a predoctoral trainee in Lowrys lab and first author of the study. The idea of using drugs to stimulate hair growth through hair follicle stem cells is very promising given how many millions of people, both men and women, deal with hair loss. I think weve only just begun to understand the critical role metabolism plays in hair growth and stem cells in general; Im looking forward to the potential application of these new findings for hair loss and beyond.

The use of RCGD423 to promote hair growth is covered by a provisional patent application filed by the UCLA Technology Development Group on behalf of UC Regents. The use of UK5099 to promote hair growth is covered by a separate provisional patent filed by the UCLA Technology Development Group on behalf of UC Regents, with Lowry and Christofk as inventors.

The experimental drugs described above were used in preclinical tests only and have not been tested in humans or approved by the Food and Drug Administration as safe and effective for use in humans.

The research was supported by a California Institute for Regenerative Medicine training grant, a New Idea Award from the Leukemia and Lymphoma Society, the National Cancer Institute (R25T CA098010), the National Institute of General Medical Sciences (R01-GM081686 and R01-GM0866465), the National Institutes of Health (RO1GM094232), an American Cancer Society Research Scholar Grant (RSG-16-111-01-MPC), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (5R01AR57409), a Rose Hills Foundation Research Award and the Gaba Fund. The Rose Hills award and the Gaba Fund are administered through the UCLA Broad Stem Cell Research Center.

Further research on the use of UK5099 is being funded by the UCLA Technology Development Group through funds from California State Assembly Bill 2664.

The rest is here:
UCLA scientists identify a new way to activate stem cells to make hair grow - UCLA Newsroom

Stem cell technique could reverse a major type of infertility – New Scientist

By adminAugust 17, 2017Stell Cell Research

Fertile sperm are rare in men with an extra sex chromosome

Dennis Kunkle Microscopy/SPL

By Andy Coghlan

Turning skin cells into sperm may one day help some infertile men have babies. Research in mice has found a way to make fertile sperm from animals born with too many sex chromosomes.

Most men have two sex chromosomes one X and one Y but some have three, which makes it difficult to produce fertile sperm. Around 1 in 500 men are born with Klinefelter syndrome, caused by having an extra X chromosome, while roughly 1 in 1000 have Double Y syndrome.

James Turner of the Francis Crick Institute in London and his team have found a way to get around the infertility caused by these extra chromosomes. First, they bred mice that each had an extra X or Y chromosome. They then tried to reprogram skin cells from the animals, turning them into induced pluripotent stem cells (iPS), which are capable of forming other types of cell.

To their surprise, this was enough to make around a third of the skin cells jettison their extra chromosome. When these cells were then coaxed into forming sperm cells and used to fertilise eggs, 50 to 60 per cent of the resulting pregnancies led to live births.

This suggests that a similar technique might enable men with Klinefelter or Double Y-related infertility to conceive. But there is a significant catch.

We dont yet know how to fully turn stem cells into sperm, so the team got around this by injecting the cells into mouse testes for the last stages of development. While this led to fertile sperm, it also caused tumours to form in between 29 and 50 per cent of mice.

What we really need to make this work is being able to go from iPS cells to sperm in a dish, says Turner.

It has to be done all in vitro, so only normal sperm cells would be used to fertilise eggs, says Zev Rosenwaks of the Weill Cornell Medical College in New York. The danger with all iPS cell technology is cancer.

Journal reference: Science, DOI: 10.1126/science.aam9046

Blood cancer: High doses of vitamin C could encourage stem cells to die – Express.co.uk

By adminAugust 17, 2017Stell Cell Research

GETTY

The study suggests it may encourage blood cancer stem cells to die.

Researchers say Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers.

They explained that certain genetic changes are known to reduce the ability of an enzyme called TET2 to encourage stem cells to become mature blood cells, which eventually die, in many patients with certain kinds of leukaemia.

The new study, published online by the journal Cell. found that vitamin C activated TET2 function in mice engineered to be deficient in the enzyme.

Study corresponding author Professor Benjamin Neel, of the Perlmutter Cancer Centre in the United States, said: "We're excited by the prospect that high-dose vitamin C might become a safe treatment for blood diseases caused by TET2-deficient leukemia stem cells, most likely in combination with other targeted therapies."

GETTY

We're excited by the prospect that high-dose vitamin C might become a safe treatment for blood diseases

Benjamin Neel

He said changes in the genetic code that reduce TET2 function are found in 10 per cent of patients with acute myeloid leukaemia (AML), 30 per cent of those with a form of pre-leukaemia called myelodysplastic syndrome, and in nearly 50 per cent of patients with chronic myelomonocytic leukaemia.

Such cancers cause anaemia, infection risk, and bleeding as abnormal stem cells multiply in the bone marrow until they interfere with blood cell production, with the number of cases increasing as the population ages.

Prof Neel said the study results revolve around the relationship between TET2 and cytosine, one of the four nucleic acid "letters" that comprise the DNA code in genes.

To determine the effect of mutations that reduce TET2 function in abnormal stem cells, the researchers genetically engineered mice such that the scientists could switch the TET2 gene on or off.

Similar to the naturally occurring effects of TET2 mutations in mice or humans, using molecular biology techniques to turn off TET2 in mice caused abnormal stem cell behaviour.

SWNS

Prof Neel said, remarkably, the changes were reversed when TET2 expression was restored by a genetic trick.

Previous work had shown that vitamin C could stimulate the activity of TET2 and its relatives TET1 and TET3.

Because only one of the two copies of the TET2 gene in each stem cell is usually affected in TET2-mutant blood diseases, the researchers hypothesised that high doses of vitamin C, which can only be given intravenously, might reverse the effects of TET2 deficiency by turning up the action of the remaining functional gene.

They found that vitamin C did the same thing as restoring TET2 function genetically.

By promoting DNA demethylation, high-dose vitamin C treatment induced stem cells to mature, and also suppressed the growth of leukaemia cancer stem cells from human patients implanted in mice.

Study first author Doctor Luisa Cimmino, of New York University Langone Health, said: "Interestingly, we also found that vitamin C treatment had an effect on leukaemic stem cells that resembled damage to their DNA.

"For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer."

The researchers found that the combination had an enhanced effect on leukaemia stem cells, further shifting them from self-renewal back toward maturity and cell death.

Dr Cimmino said the results also suggest that vitamin C might drive leukaemic stem cells without TET2 mutations toward death, given that it turns up any TET2 activity normally in place.

Corresponding author Professor Iannis Aifantis, also of NYU Langone Health, added: "Our team is working to systematically identify genetic changes that contribute to risk for leukaemia in significant groups of patients.

"This study adds the targeting of abnormal TET2-driven DNA demethylation to our list of potential new treatment approaches."

Read the original here:
Blood cancer: High doses of vitamin C could encourage stem cells to die - Express.co.uk

Stem cell agency eyes survival options – Capitol Weekly

By adminAugust 17, 2017Stell Cell Research

News

by DAVID JENSEN posted 08.14.2017

Californias $3 billion stem cell research agency, which is facing its financial demise in a few short years, has formed a team of its directors to tackle transition planning and examine possible alternatives, including ones that would extend its life.

The first meeting of the group of directors is tentatively scheduled for Sept. 18.Jonathan Thomas, chairman of the governing board of theCalifornia Institute for Regenerative Medicine(CIRM), as the agency is formally known, said earlier this summer:

The legislature has asked that we put together and start thinking about a transition plan, which can contemplate a variety of factors.In response to a question last week, a spokesman for the agency,Kevin McCormack, said that a notice with more details would be posted 10 days prior to the meeting.

At a meeting in June, Thomas laid out the need for the transition team. He said all options are on the table including asking the legislature for cash or to place a measure on the ballot for more bond funding.

The agencys only real source of money is state bonds, authorized by voters in 2004. It has roughly $600 million left. The agency has projected it will run out of cash for new awards in mid 2020, althoughthat could vary, depending on whether it slows down the pace of awards.

Several directors at the board meeting in June expressed a sense of urgency about dealing with the fate of the agency. CIRM DirectorJeff Sheehy, a member of the San Francisco board of supervisors and an HIV/AIDS patient advocate, voiced concern about the uncertain nature of the agencys future.

Sheehy said,It seems to me that we will be talking about a substantial scaling back of the organization in2020.Weve kind of created this expectation that we were going to go to 2018 and come back with new money.

Sheehy referred to talk that a new bond initiative might be launched in 2018, a move that the boards former chairman,Robert Klein, has publicly advanced. Sheehy said, however, that he spoke with Klein, who told him that he wasnow considering 2020 instead.Kleins method would require the gathering of hundreds of thousands of valid voter signatures to place the proposal on the ballot and would bypass the legislature.

The year 2020 includes a presidential election, which has higher voter turnout and generally is considered a better time to win approval of bond measures. Presumably, the agency might be able to secure extra funding to span any financial gap or, alternatively, lower the frequency of awards to stretch out the cash.

The members of the transition group are Thomas, Sheehy,Art Torres, Steve Juelsgaard, Joe Panetta, Kristiina Vuori, Linda Malkas, Diane Winokur, Shlomo Melmed, Al RowlettandJudy Gasson.Short bios on each of them can be found via this page.

TheCalifornia Stem Cell Reportwill carry an item with the date and location of the September meeting when it becomes available. Eds Note:DavidJensenis a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report,where this story first appeared.He has published more than 4,000 items on California stem cell matters in the past 11 years.

Support for Capitol Weekly is Provided by:

Read this article:
Stem cell agency eyes survival options - Capitol Weekly

Deval Patrick’s 10-year, $1B life sciences plan bears fruit in Mass. – The Recorder

By adminAugust 17, 2017Stell Cell Research

BOSTON In his offices at Boston Childrens Hospital, Leonard Zon is busily developing cutting-edge stem cell therapies surrounded by fellow researchers, lab equipment and 300,000 striped, transparent zebrafish.

Zons lab and the zebrafish are the results of an initiative begun nearly a decade ago to make Massachusetts one of the countrys premier life sciences incubators.

That 2008 initiative, signed by former Democratic Gov. Deval Patrick, committed Massachusetts to spending $1 billion over 10 years to jump-start the life sciences sector attracting the best minds, research facilities and the venture capital funding.

By most yardsticks, Patricks gamble has paid off. Massachusetts, and the greater Boston area in particular, are now seen as a top life sciences hub.

For Zon, and other life sciences leaders, the support has been transformative.

In 2013, the Massachusetts Life Sciences Center, which is charged with distributing the state funds, awarded a $4 million grant to Childrens Hospital to help establish the Childrens Center for Cell Therapy. Some of the money went toward replacing the original aquaculture facilities at Zons lab with state-of-the-art systems.

Zon said the changes helped him pursue stem cell therapies taking tissues grown from stem cells aimed at thwarting specific diseases and transplanting them into a diseased organ. Zon said his lab helped develop a drug for treating a blood disease known as Diamond Blackfan anemia in part by developing zebrafish models of the disease.

Massachusetts is the best place in the world for biotechnology, he said. Its been life-changing for us.

Zons experience isnt unique.

NxStage Medical, Inc., a medical technology company founded in 1998 in Lawrence focused on end-stage renal disease and acute kidney failure, received nearly $1.8 million in tax incentives through the program. In 2013, Woburn-based Bio2 Technologies received $1 million in loan financing, helping it develop bone graft substitute implants.

The states reputation as a magnet for life sciences also can be seen in the surge of construction in Boston and Cambridge, particularly around the Kendall Square area, where glass-lined office and research buildings have sprouted.

Travis McCready, CEO of the Massachusetts Life Sciences Center, also pointed to the influx of grant money from the National Institutes of Health and funds from world-class academic and research institutions.

By pretty much any measure we are considered the leading life sciences ecosystem in the U.S., and among the leading ecosystems in the world, McCready said.

McCready said the 2008 initiative helped create a framework for that growth, even as he acknowledged that not every company or research effort that receives funding succeeds.

Some of these startups are going to fail, but ideas will be tested and intellectual property will be created, he said. Failure is not a negative.

McCready said a top goal of the program is to develop the next generation of researchers. The center funds over 500 life sciences internships each year with about a quarter of those landing full-time jobs at the company where they interned.

He said that talent pool is critical to the next stage in the life science revolution: bio-manufacturing and digital health.

Bio-manufacturing refers to the ability of research labs and life science companies to take their breakthroughs and start manufacturing them on a large scale. He pointed to a decision by Kendall Square-based Alnylam Pharmaceuticals to open a 200,000-square-foot manufacturing space in Norton, just 45 minutes away.

He said the state also is hoping to builds up the digital health sector, where large sets of scientific data are used to look for new therapies and how best to deliver those medicines inexpensively.

Today we are the undisputed global leader in the field, Patrick said this week in a statement to The Associated Press. Public investment not only catalyzed hundreds of millions of dollars in private investment and created thousands of jobs, but contributes meaningfully to the development of life changing treatments and cures for people around the world.

Republican Gov. Charlie Baker is hoping to building on the initiative.

In June, Baker announced a proposal to dedicate $500 million over five years to continue strengthening the life sciences sector with a focus on public infrastructure, research and development, workforce training and education.

Baker said hes committed to supporting the public-private partnerships and strategic investments that have made Massachusetts a global leader in the life sciences.

Go here to see the original:
Deval Patrick's 10-year, $1B life sciences plan bears fruit in Mass. - The Recorder